Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus

Summary

The purpose of this study is the determine whether a new compound, called lapatinib, can be effective in shrinking cancerous tumors of the esophagus that have recurred or spread somewhere else in the body. They also want to determine the toxicity of this regimen. Lapatinib blocks 2 receptors that sometimes are present on cancer cells (called epidermal growth factor receptor, and the Erb B2 receptor). It is possible that blocking these receptors may decrease the growth of the cancer cells.

Timeline

Start

2005-10

Primary completion

2006-06

Completion

2007-09

Outcome

Outcome not reported

Stopped: “notification from sponsor”

Drugs

Indications